Emami Limited Showcases Strong Recovery with 11% Growth in Q3FY26

3 min read     Updated on 06 Feb 2026, 11:24 PM
scanx
Reviewed by
Radhika SScanX News Team
Overview

Emami Limited presented strong operational performance in its investor presentation, highlighting 7% domestic sales growth in FY25 and robust 11% growth in Q3FY26. The company successfully transformed its portfolio from niche to mainstream segments, with new age products increasing from 7% to 20% share. D2C brands revenue nearly doubled from FY23 to FY25, while international business maintained 11% five-year CAGR despite challenges. Key brands including Navratna, Dermicool, BoroPlus, and Zandu Healthcare delivered strong double-digit growth, supported by strategic brand rejuvenations and digital transformation initiatives.

31946081

*this image is generated using AI for illustrative purposes only.

Emami Limited presented its comprehensive investor presentation for the Nuvama India Conference 2026 and IIFL's 17th Enterprising India Global Investors' Conference, showcasing strong operational performance and strategic growth initiatives across its diversified portfolio.

Strong FY25 Performance Despite Market Challenges

The company delivered resilient performance in FY25 despite facing higher inflation and subdued rural demand. Emami demonstrated strong cost discipline and agile execution while gaining market share across key categories.

Performance Metric FY25 Growth
Domestic Net Sales (Value) +7%
Domestic Net Sales (Volume) +4%
International Net Sales (Constant Currency) +5%
International Net Sales (INR) +4%
EBIDTA +8%
Profit Before Tax +13%
Profit After Tax +11%

Key brands delivered exceptional growth with Navratna and Dermicool growing by 18%, BoroPlus expanding by 14%, and Zandu Healthcare achieving 12% growth. The company's margin expansion was driven by cost optimization and premiumization strategies, with gross margins improving by 100 basis points and EBIDTA margins expanding by 40 basis points.

Strategic Portfolio Transformation

Emami's core brands have successfully diversified from niche segments into mainstream categories. The company's new age and mainstream portfolio share increased significantly from 7% in FY20 to 20% in FY25 for domestic business.

Brand Category FY20 New Age Share FY25 New Age Share
BoroPlus 9% 23%
Kesh King 23% 41%
Smart and Handsome 13% 17%
Healthcare 4% 26%

The company has undertaken significant brand rejuvenations, including relaunching Kesh King as Kesh King Gold with new formulation and positioning, and rebranding Fair & Handsome to Smart & Handsome to expand into the grooming universe worth ₹6,700 crore.

Digital and D2C Growth Momentum

Emami's D2C brands revenue nearly doubled in FY25 compared to FY23, with gross margins improving dramatically from 47.2% in FY23 to 60.2% in FY25. The company's digital transformation includes strategic investments in startups and expansion of organized channel presence.

Channel Development FY20 FY25
Organized Channels Share 11% 29%
E-Commerce Share 0% 12%
Modern Trade Share 7% 11%

ZanduCare, the company's digital healthcare ecosystem, has shown impressive growth with approximately 100 digital-first products launched and 3.2x sales growth from FY21 to FY25. The platform has served over 21 lakh cumulative orders and achieved cumulative GMV of approximately ₹120 crore.

International Business Resilience

Despite geopolitical challenges, Emami's international business maintained steady performance with 11% five-year CAGR. The business accounts for 17% of total revenue in FY25, up from 15% in FY20. The company has strategically localized operations with 80% production and sourcing now outside India and 85% of international workforce locally hired.

Strong Q3FY26 Recovery

After facing challenges in H1FY26 due to weak summers, unseasonal rains, and GST transition impacts, Emami delivered strong 11% growth in Q3FY26. The quarter showed robust performance across the portfolio with strong growth in key brands including BoroPlus, Zandu, Mentho Plus Balm, Kesh King Gold, Navratna, Dermicool, Smart and Handsome, and The Man Company.

Quarter Performance Growth Rate Key Impact Factors
Q1FY26 0% Weak summers and unseasonal rains
Q2FY26 -10% GST transition and excess rainfall
Q3FY26 11% Strong growth across portfolio

Financial Strength and Capital Allocation

Emami maintains strong financial health with disciplined capital deployment. From FY21 to 9MFY26, the company distributed ₹2,024 crore in cumulative dividends, conducted ₹663 crore in cumulative buybacks, and invested approximately ₹985 crore in cumulative acquisitions and strategic investments. The company holds over ₹1,000 crore in net cash as of 31st December 2025, reinforcing its ability to fund growth while rewarding shareholders.

Historical Stock Returns for Emami

1 Day5 Days1 Month6 Months1 Year5 Years
+0.21%+5.00%-4.27%-17.86%-13.87%+0.33%

Emami Reports Strong Q3FY26 Performance with 11% Revenue Growth and Regulatory Compliance

3 min read     Updated on 04 Feb 2026, 02:47 PM
scanx
Reviewed by
Ashish TScanX News Team
Overview

Emami Limited delivered exceptional Q3FY26 performance with consolidated net sales of ₹1,147 crore (11% growth) and net profit of ₹319 crore (15% growth). The company demonstrated strong margin expansion with EBITDA margin improving to 33.4%. All major brands showed healthy growth led by BoroPlus Range at 16%. The company fulfilled regulatory compliance by publishing results in newspapers and declared a second interim dividend of ₹6 per share.

31742251

*this image is generated using AI for illustrative purposes only.

Emami Limited has delivered exceptional financial performance in Q3FY26, reporting consolidated net sales of ₹1,147 crore compared to ₹1,036 crore in the corresponding quarter of the previous year. The consumer goods company achieved consolidated net profit of ₹319 crore, marking a significant 15% increase from ₹279 crore in the same period last year.

Outstanding Financial Performance

The company's quarterly results demonstrate robust growth across all key financial metrics. Net sales growth of 11% year-on-year, combined with the 15% increase in net profit, showcases Emami's ability to drive both top-line and bottom-line expansion. The company reported EBITDA of ₹384 crore, representing a substantial 13% increase from ₹339 crore in the corresponding quarter of the previous year.

Financial Metric: Q3FY26 Q3FY25 Growth (%)
Net Sales: ₹1,147 crore ₹1,036 crore +11%
Revenue from Operations: ₹1,152 crore ₹1,050 crore +10%
Net Profit: ₹319 crore ₹279 crore +15%
EBITDA: ₹384 crore ₹339 crore +13%
EBITDA Margin: 33.4% 32.3% +110 bps
PBT before Exceptionals: ₹355 crore ₹301 crore +18%

Exceptional Margin Expansion

Emami's EBITDA margin improved significantly to 33.4% in Q3FY26, compared to 32.3% in the same period last year, reflecting enhanced operational efficiency and superior cost management. This margin expansion of 110 basis points demonstrates the company's ability to optimize its cost structure while maintaining strong growth momentum across its business operations. Gross margins also expanded to 70.6%, an improvement of 30 basis points.

Strong Domestic and International Performance

The domestic business delivered growth of 11%, driven by robust volume growth of 9%. All major brands registered healthy performance during the quarter, with BoroPlus Range leading growth at 16%, followed by Kesh King Range at 10%, Pain Management Range at 8%, and Healthcare Range at 7%. The international business recorded sales growth of 9%, contributing 15% to overall sales, with strong performance across SAARC, MENA, and CIS regions.

Brand Performance: Q3FY26 Growth
BoroPlus Range: +16%
Kesh King Range: +10%
Pain Management Range: +8%
Healthcare Range: +7%
Male Grooming Range: +4%
7 Oils in One: +41%

Strategic Innovation and Product Launches

During the quarter, Emami launched several new products including Kesh King Gold Advanced Hair Growth Serum, BoroPlus Deeply Moisturising Lip Balm, Zandu Apple Cider Vinegar Effervescent Tablets, and Zandu Good Gut Constipation Relief Tablets. The Man Company introduced Vitamin C and Anti Acne Facewash, Moisturizing Gel Cream, and Anti Dandruff Shampoo, further strengthening its premium male grooming segment.

Regulatory Compliance and Publication

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Emami Limited published its unaudited financial results for the quarter and nine months ended December 31, 2025, in newspapers. The results were published in "Business Standard" (English Version) and "Aajkal" (Bengali Version) on February 5, 2026, following Board approval on February 4, 2026.

Publication Details: Information
Publication Date: February 5, 2026
Board Approval Date: February 4, 2026
English Newspaper: Business Standard
Bengali Newspaper: Aajkal
Regulatory Requirement: SEBI Regulation 47

Interim Dividend Declaration

The Board of Directors declared a second interim dividend of 600%, amounting to ₹6 per share for FY26. With this declaration, the total dividend for the nine months ended FY26 stands at ₹10 per share, demonstrating the company's confidence in its financial strength and commitment to rewarding shareholders.

Source: Emami Limited Investor Presentation Q3FY26, Business Standard newspaper publication

Historical Stock Returns for Emami

1 Day5 Days1 Month6 Months1 Year5 Years
+0.21%+5.00%-4.27%-17.86%-13.87%+0.33%

More News on Emami

1 Year Returns:-13.87%